Phase III Clinical Study Using BSD Medical's Systems for Treating Pancreatic Cancer to Be Announced at ASCO

"BSD Medical Corp. (NASDAQ:BSDM) announced today that a team of researchers headed by Professor Rolf D. Issels will be announcing at the upcoming annual American Society of Clinical Oncology (ASCO) conference that a Phase III clinical study is underway involving the combined use of hyperthermia therapy and chemotherapy in treating patients with pancreatic cancer. This announcement follows the successful conclusion of a Phase II clinical trial conducted in Munich, Germany using a combination of hyperthermia therapy and chemotherapy to treat patients with pancreatic cancer. All hyperthermia treatments used for this study will be delivered using BSD-2000 hyperthermia systems. The ASCO conference held in Chicago, Illinois will run May 30 through June 3.

Pancreatic cancer is the fourth leading cause of cancer death in men and women. The American Cancer Society has projected 37,170 new cases and 33,370 deaths from the disease in the United States this year. While the use of hyperthermia therapy in treating some other forms of cancer has been heavily researched, little has been known about the potential of the therapy in treating pancreatic cancer patients, a deadly cancer for which better treatments are urgently needed. "